183 related articles for article (PubMed ID: 9316848)
1. Prevention of tolerance to the antinociceptive effects of systemic morphine by a selective cholecystokinin-B receptor antagonist in a rat model of peripheral neuropathy.
Idänpään-Heikkilä JJ; Guilbaud G; Kayser V
J Pharmacol Exp Ther; 1997 Sep; 282(3):1366-72. PubMed ID: 9316848
[TBL] [Abstract][Full Text] [Related]
2. In mononeuropathic rats, the enhancement of morphine antinociception by L-365,260, a selective CCK(B) receptor antagonist, depends on the dose of systemic morphine and stimulus characteristics.
Idänpään-Heikkilä JJ; Perrot S; Guilbaud G; Kayser V
Eur J Pharmacol; 1997 May; 325(2-3):155-64. PubMed ID: 9163562
[TBL] [Abstract][Full Text] [Related]
3. The selective cholecystokininB receptor antagonist L-365,260 diminishes the expression of naloxone-induced morphine withdrawal symptoms in normal and neuropathic rats.
Kayser V; Idänpään-Hekkilä JJ; Christensen D; Guilbaud G
Life Sci; 1998; 62(10):947-52. PubMed ID: 9496717
[TBL] [Abstract][Full Text] [Related]
4. Complete prevention but stimulus-dependent reversion of morphine tolerance by the glycine/NMDA receptor antagonist (+)-HA966 in neuropathic rats.
Christensen D; Guilbaud G; Kayser V
Anesthesiology; 2000 Mar; 92(3):786-94. PubMed ID: 10719957
[TBL] [Abstract][Full Text] [Related]
5. The antinociceptive effect of combined systemic administration of morphine and the glycine/NMDA receptor antagonist, (+)-HA966 in a rat model of peripheral neuropathy.
Christensen D; Idänpään-Heikkilä JJ; Guilbaud G; Kayser V
Br J Pharmacol; 1998 Dec; 125(8):1641-50. PubMed ID: 9886755
[TBL] [Abstract][Full Text] [Related]
6. Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats.
Nichols ML; Bian D; Ossipov MH; Lai J; Porreca F
J Pharmacol Exp Ther; 1995 Dec; 275(3):1339-45. PubMed ID: 8531101
[TBL] [Abstract][Full Text] [Related]
7. The enhancement of morphine antinociception by a CCKB receptor antagonist in the rat depends on the phase of inflammation and the intensity of carrageenin-induced hyperalgesia.
Perrot S; Idänpään-Heikkilä JJ; Guilbaud G; Kayser V
Pain; 1998 Feb; 74(2-3):269-74. PubMed ID: 9520241
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.
Xie JY; Herman DS; Stiller CO; Gardell LR; Ossipov MH; Lai J; Porreca F; Vanderah TW
J Neurosci; 2005 Jan; 25(2):409-16. PubMed ID: 15647484
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
[TBL] [Abstract][Full Text] [Related]
10. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze.
Kõks S; Soosaar A; Võikar V; Bourin M; Vasar E
Neuropeptides; 1999 Feb; 33(1):63-9. PubMed ID: 10657473
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a peripheral component in the enhanced antinociceptive effect of a low dose of systemic morphine in rats with peripheral mononeuropathy.
Kayser V; Lee SH; Guilbaud G
Neuroscience; 1995 Jan; 64(2):537-45. PubMed ID: 7700537
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of morphine and clomipramine analgesia by cholecystokinin -B antagonist CI-988 in diabetic rats.
Coudoré-Civiale MA; Courteix C; Boucher M; Méen M; Fialip J; Eschalier A; Ardid D
Neurosci Lett; 2000 May; 286(1):37-40. PubMed ID: 10822147
[TBL] [Abstract][Full Text] [Related]
14. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat.
Dourish CT; O'Neill MF; Coughlan J; Kitchener SJ; Hawley D; Iversen SD
Eur J Pharmacol; 1990 Jan; 176(1):35-44. PubMed ID: 2311658
[TBL] [Abstract][Full Text] [Related]
15. L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: electrophysiological and behavioural studies.
Xu XJ; Hoffmann O; Wiesenfeld-Hallin Z
Neuropeptides; 1996 Apr; 30(2):203-6. PubMed ID: 8771563
[TBL] [Abstract][Full Text] [Related]
16. Caerulein may potentiate morphine-induced antinociception by cholecystokinin-A and/or cholecystokinin-B receptor mechanisms.
Rezayat M; Oreizi S; Zarrindast MR
Gen Pharmacol; 1997 Feb; 28(2):337-40. PubMed ID: 9013214
[TBL] [Abstract][Full Text] [Related]
17. Effects of caerulein and CCK antagonists on tolerance induced to morphine antinociception in mice.
Zarrindast MR; Zabihi A; Rezayat M; Rakhshandeh H; Ghazi-Khansari M; Hosseini R
Pharmacol Biochem Behav; 1997 Sep; 58(1):173-8. PubMed ID: 9264087
[TBL] [Abstract][Full Text] [Related]
18. Effects of spinal cholecystokinin receptor antagonists on morphine antinociception in a model of visceral pain in the rat.
Friedrich AE; Gebhart GF
J Pharmacol Exp Ther; 2000 Feb; 292(2):538-44. PubMed ID: 10640290
[TBL] [Abstract][Full Text] [Related]
19. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.
Singh L; Oles RJ; Field MJ; Atwal P; Woodruff GN; Hunter JC
Br J Pharmacol; 1996 Jul; 118(5):1317-25. PubMed ID: 8818359
[TBL] [Abstract][Full Text] [Related]
20. Spinal effect of the cholecystokinin-B receptor antagonist CI-988 on hyperalgesia, allodynia and morphine-induced analgesia in diabetic and mononeuropathic rats.
Coudoré-Civiale MA; Courteix C; Fialip J; Boucher M; Eschalier A
Pain; 2000 Oct; 88(1):15-22. PubMed ID: 11098095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
